Contact this trialFirst, we need to learn more about you.
Monoclonal Antibodies
Dupilumab for Asthma
Recruiting2 awardsPhase 4
Metairie, Louisiana
This trial is testing whether dupilumab can prevent or slow the rate of decline in lung function in patients with uncontrolled moderate to severe asthma, compared to standard of care therapy. The trial will last for 3 years, with a follow-up period of up to 12 weeks after treatment.
Fill-in a few details and create your profileHaving a profile will help us send you recommended trials and speed up your application in the future.
We will keep your details privateWe won’t share unless you give us permission. By completing this form you agree to our privacy policy
Get in touch with the study teamWe’ll send your responses to the study team and help you to setup your first screening. This is not the start of informed consent. Screening happens between you and the trial.